Hikma Resumes Launch Of Advair Rival
Follows FDA Approval Of ANDA Amendment That Forced Pause
Hikma has restarted launch activities for its generic version of GSK’s Advair respiratory blockbuster in the US, after the FDA gave the go-ahead following approval of an ANDA amendment.
